Related Experiment Video
Updated: Jun 17, 2026

08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Gene therapy for severe combined immunodeficiency: are we there yet?
Marina Cavazzana-Calvo1, Alain Fischer
1INSERM U768 and Université Paris Descartes, Paris, France. m.cavazzana@nck.aphp.fr
The Journal of Clinical Investigation
|June 6, 2007
Summary
Gene therapy offers a promising alternative for treating hematopoietic diseases when HLA-matched donors are unavailable. This review explores gene-modified autologous transplantation for SCID, addressing safety and efficacy.
Area of Science:
- Hematology
- Immunology
- Gene Therapy
Background:
- Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for hematopoietic diseases.
- Treatment success relies on HLA-matched sibling donors; alternatives are limited.
- HLA-mismatched related donors cause severe immunological complications.
Purpose of the Study:
- To review the advantages and limitations of gene therapy for severe combined immunodeficiency (SCID).
- To discuss gene-modified autologous bone marrow transplantation as an alternative strategy.
- To address safety concerns, including insertional mutagenesis.
Main Methods:
- Review of existing literature on gene therapy for hematopoietic diseases.
- Analysis of gene-modified autologous transplantation approaches.
- Discussion of safety improvements and technological advancements.
Main Results:
- Gene therapy can circumvent immunological issues associated with HLA-mismatched HSCT.
- Insertional mutagenesis remains a significant safety concern.
- Technological advancements are improving the safety profile of gene therapy.
Conclusions:
- Gene-modified autologous transplantation is a viable alternative for SCID when matched donors are unavailable.
- Ongoing research focuses on mitigating risks like insertional mutagenesis.
- Gene therapy holds significant potential for curing inherited and acquired hematopoietic disorders.
Related Concept Videos
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...

